Core Viewpoint - The internal conflict within Kexing Biologics has intensified, particularly surrounding a significant cash dividend distribution, which has become a focal point for shareholder disputes and board control [1][10]. Group 1: Shareholder Disputes - Kexing Biologics is experiencing a power struggle between two factions led by Li Jiaqiang and Yin Weidong, with the latter being one of the company's founders [5]. - A special shareholders' meeting was held to elect a new board, proposed by Sequoia Capital, which resulted in the dismissal of the current board and the election of ten new members [3][5]. - Li Jiaqiang's faction claims the election is invalid, asserting that the meeting was improperly conducted and that their board remains the only legitimate governing body [6][8]. Group 2: Dividend Distribution - Kexing Biologics announced a total cash dividend of $7.448 billion, with an initial payment of $55 per share, which is expected to deplete over 70% of the company's cash reserves [10][11]. - The dividend distribution is seen as a compensatory measure for shareholders, particularly for Li Jiaqiang's faction, who have not received direct dividends from the operational entity, Beijing Kexing Zhongwei [11][12]. - The distribution has sparked controversy, with opposing factions accusing each other of attempting to manipulate the situation for personal gain [12]. Group 3: Regulatory and Compliance Issues - Kexing Biologics faces potential delisting from NASDAQ if it fails to submit a compliance plan by the deadline [13]. - The company is currently working to restore its stock trading and appoint a new auditing firm to address regulatory concerns [13].

Core Viewpoint - The article discusses the internal conflicts within Sinovac Biotech, highlighting the company's significant financial performance and the ongoing power struggle among its shareholders and board members [5][18][21]. Group 1: Company Overview - Sinovac Biotech, known for its COVID-19 vaccine, has reported revenues exceeding 130 billion yuan and a net profit of over 96 billion yuan from 2021 to 2022, resulting in a net profit margin of approximately 73.8% [11][16]. - The company has been suspended from trading for six years due to internal disputes, indicating ongoing governance issues [21]. Group 2: Shareholder Conflict - A recent shareholder meeting in Antigua and Barbuda involved a proposal to remove current board members and elect new candidates nominated by SAIF Partners, reflecting deep divisions among shareholders [18][22]. - The company announced a massive special dividend payment of up to 7.5 billion USD, leaving it with 2.8 billion USD in cash after the distribution [22][23]. Group 3: Historical Context - The founder, Weidong Yin, has a background in public health and has been pivotal in the company's development since its establishment in 2001 [42][62]. - Sinovac's history includes rapid advancements in vaccine development, notably during the SARS outbreak, which laid the groundwork for its later success with COVID-19 vaccines [60][61].

Core Viewpoint - The internal conflicts within Kailitai (300326.SZ) continue, with significant disagreements over the election of the new chairman, management changes, and the contentious share repurchase issue, leading to potential risks for the company [1][2][14]. Group 1: Internal Conflicts - The board of directors' election revealed deep divisions between the second-largest shareholder and the first and third shareholders, affecting key decisions such as the chairman's election and management appointments [1][3]. - The new chairman, Cai Zhongxi, was elected with 4 votes against 3 for the candidate Wang Chong, representing the first and third shareholders [1][5]. - Management changes included the appointment of Xia Tian as the general manager and Guo Haibo as the board secretary, amidst disagreements over these appointments [1][7]. Group 2: Share Repurchase Disputes - The ongoing dispute regarding the share repurchase from Ligetai has resurfaced, with the board previously voting to issue a repurchase notice, but the decision faced opposition from key stakeholders [8][10]. - The board's recent meeting did not pass the proposal to send a repurchase notice, with votes split and some members calling for more information before making a decision [9][11]. - The repurchase agreement was triggered due to Ligetai's failure to complete an IPO by December 31, 2024, leading to legal actions from the second-largest shareholder [8][12]. Group 3: Internal Control Issues - Kailitai is facing internal control problems, with auditors unable to obtain sufficient evidence regarding the valuation of equity investments and related party transactions, leading to a "non-standard" audit opinion for the 2024 financial report [2][14]. - The company announced a delay in the disclosure of its 2024 annual report due to significant disagreements with auditors, which may result in further regulatory scrutiny [14][15]. Group 4: Shareholder Actions - The second-largest shareholder, represented by Yuan Zheng and Wang Zhengmin, has been increasing their stake in Kailitai, now holding approximately 6.38% of the shares, which is close to the first shareholder's 6.99% [15][16]. - The ongoing increase in shareholding indicates a potential power struggle for control and influence over Kailitai's strategic direction [16].

Core Viewpoint - The internal conflict between the core management of Zhenxin Technology and its controlling shareholder, Chengdu Guoteng Electronics Group, has intensified, leading to the rejection of key proposals at the annual shareholder meeting [2][3]. Group 1: Shareholder Meeting and Proposals - The annual shareholder meeting of Zhenxin Technology took place on April 22, where several key proposals, including the 2024 Board of Directors' work report, were rejected due to opposition from Guoteng Group [3][4]. - Guoteng Group's chairman, Gao Hong, opted for online voting to avoid potential disputes at the meeting, indicating the tense atmosphere surrounding the event [3][4]. - The rejection of the proposals highlights the ongoing conflict between the management and the controlling shareholder, with questions raised about how to address the rejected proposals moving forward [3][4]. Group 2: Reasons for Opposition - Gao Hong criticized the board for failing to act in the best interests of the company and its shareholders, citing a 44% decline in net profit while the chairman received a 10.6% salary increase [4]. - Concerns were raised about potential conflicts of interest regarding board members' connections to other companies with similar business operations [4]. Group 3: Shareholder Dynamics - Guoteng Group holds 29.21% of Zhenxin Technology's shares, with the actual control resting with He Yan, who holds 51% of the shares, leading to claims of decision-making being "hijacked" by minority shareholders [5][6]. - The management expressed frustration over the lack of communication and cooperation from Guoteng Group, while Guoteng Group countered that they have been cooperative when it benefits the company [6][8]. Group 4: Future Outlook and Demands - The management of Zhenxin Technology desires the dissolution of Guoteng Group to achieve a more decentralized ownership structure, which would eliminate a controlling shareholder [7][8]. - Guoteng Group's stance is focused on stability and development, advocating for lawful governance and adherence to regulations by all shareholders [8][9].